BIA Networking Lunch - Oxford
Join us in Oxford for another popular BIA networking lunch. This a great opportunity to network with colleagues, meet new contacts and hear from local BIA members.
We are pleased to announce that the Office for Life Sciences (OLS) will also be joining us for a special Brexit-focused session at the start of the event.
11:10 Brexit-focused session with the Office for Life Sciences
The Office for Life Sciences (OLS) will be holding a workshop to help inform and update member companies prepare for EU Exit.
OLS will deliver presentations on the following areas: Introduction to the Office for Life Sciences; Regulations update; Continuity of Supply; Trader readiness; Workforce; and Q&A.
12.00: Lunch and networking
13.00: Steve Bates, CEO, BIA
13.10: Piers Scrimshaw-Wright, CEO, Oxford Science Park
13.20: Company presentations
Representatives from Immunocore, OMass Therapeutics, and VMIC will join us to give short presentations on their work and recent developments.
14.00: Networking - tea, coffee, and biscuits provided
Helen works in the Office for Life Science’s EU Exit and International Trade team, with a focus on international trade, particularly intellectual property, services, and digital trade. Before joining OLS, Helen worked for a number of different government departments, including the Department of Health and Social Care, Department for Work and Pensions, and Defra.
Sharon Egan works for Office for Life Sciences in the investments and engagement team. Preceding this she worked at the Department of Health and Social Care where she led a Bill team and before that, worked in public health.
She has also worked in a range of Government departments and bodies including HMRC, the Healthcare and Care Quality Commission, Food Standards Agency and as a regulator in HSE. Once upon a time she was a scientist in genetics and microbiology, specialising in antibiotic genes.
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.
A science and business park specialist, Piers is the Science Park's Chief Executive, responsible for leading the on-site team, asset management and the ambitious development plans. Piers is a qualified chartered surveyor with over 20 years’ experience in development and asset management. A former Director at Arlington, then Goodman, Piers was responsible for the development of Uxbridge Business Park (with significant HQ lettings to Bristol-Myers Squibb and Amgen), the acquisition and development of Colworth Science Park and Harwell Oxford, and then an ambitious development programme in France, Spain and Germany. More recently, he has been involved in a niche UK Science Park start-up company. Piers began his career at GVA in London.
I joined Immunocore as Chief Commercial Officer in October 2017 to bring the innovative and transformational science at Immunocore to market. Having stepped into the role of CEO in February 2018, I am delighted to lead the vision for one of the UK’s top biotechnology companies. With more than 30 years of experience in the pharmaceutical sector, I have held numerous cross-functional roles spanning sales, marketing, commercial strategy, country management and regional leadership with Eli Lilly & Co. Additionally, having worked in roles that encompass corporate strategy and business development, I can bring a wealth of knowledge and experience to the BIA Board and continue to help move the BIA in its forward trajectory.
At Lilly, I served in a number of global leadership positions across multiple therapeutic areas and geographies including as Vice President International Business Unit Leader Oncology, President Biomedicines Business Unit, Australia, Canada and Europe and Snr VP Digital Ventures as regional head and country head of a company with commercial, manufacturing and research presence. I represented the company directly with governments across multiple countries so I have a deep understanding of the policy and operational challenges faced by the industry. I have also served as Chairman of the European Markets Committee at EFPIA. I was on the Board of the ABPI for over 6 years and was also Chair of the American Pharma Group.
Dr Ali Jazayeri
Ali Jazayeri joined OMass Therapeutics in October 2018. He was previously Chief Technology Officer of Heptares Therapeutics, a company he joined in 2007 as one of the first scientists and was involved in the transfer of the GPCR stabilisation technology from the MRC Laboratory of Molecular Biology to Heptares. Following successful implementation and industrialisation of the original technology, he led the development of novel methodologies that significantly increased the efficiency and reach of the technology and resulted in the generation of novel IP. In addition, he was one of the key members of the executive sub-team that lead the acquisition of G7 therapeutics, spin out company from University of Zurich and went on to lead the further development and integration of their technology as part of the Heptares Zurich management team. Prior to Heptares, Ali worked as a post-doctoral scientist in Clare Hall Laboratories (a Cancer Research UK institute) and Kudos Pharmaceuticals (later acquired by AstraZeneca) where he carried out research on the role of cell cycle checkpoint kinases in DNA damage response pathways. He has a BSc in Genetics from University of Manchester and obtained his PhD in molecular biology with Prof Steve Jackson at the Gurdon Institute from University of Cambridge.
Rachael is an experienced senior manager with over 10 years experience in big pharma at GSK. A strong and broad background of GMP manufacture has been obtained in her career from working in multiple disciplines across Operations, Technical and Quality roles. This has led to leadership experience in organisation design and development, extensive knowledge in quality systems and has led major change projects and lean initiatives. She was formally a Senior Manufacturing Manager responsible for leading Operations for a CDMO.
The Oxford Science Park
Free for members and non-members
By registering to this event you accept our Terms & Conditions